Table of Contents
NeoGenomics, Inc., a leading provider of oncology diagnostic solutions that enable precision medicine, today announced that it has finalized a civil settlement with the Department of Justice on behalf of the Office of Inspector General of the U.S. Department of Health and Human Services, resolving an investigation concerning consulting services provided to certain health care providers for laboratory testing services.
What the NeoGenomics DOJ Settlement Investigation Involved
The investigation centered on consulting services NeoGenomics provided to health care providers as part of its Laboratory Collaboration Initiative program. The company self-disclosed the matter to OIG in November 2021, well before the settlement was finalized, a distinction that shaped how the case was ultimately resolved.
DOJ Acknowledged the Company’s Cooperation
As the DOJ acknowledged in the settlement agreement, NeoGenomics cooperated with the government’s investigation into the matter. This acknowledgment of voluntary disclosure and cooperation often plays a meaningful role in how settlement terms are negotiated in healthcare compliance cases involving self-reported issues.
Financial Terms of the Settlement
The company has agreed to pay $9,813,260 plus interest at a rate of 4.250% per annum from January 16, 2026, to the United States to resolve the matter. NeoGenomics previously disclosed in its SEC filings that it had accrued a reserve of $11.2 million to cover potential damages and liabilities associated with the investigation, meaning the final settlement amount came in below its own prior financial reserve.
What the Reserve Suggests About the Settlement Outcome
The gap between the $11.2 million reserve and the finalized $9.8 million settlement suggests the company had prepared for a potentially larger financial liability, and the actual resolution came in more favorably than its own worst-case planning had anticipated.
NeoGenomics’ Response to the DOJ Settlement
Tony Zook, chief executive officer, commented, “We are pleased to resolve this legacy matter. The resolution of this voluntary disclosure will allow the Company to continue moving forward with its vision and commitment to advancing personalized cancer care.” Zook’s characterization of the matter as a “legacy” issue signals the company’s intent to frame this settlement as closed business rather than an ongoing compliance concern.
No Admission of Liability
The Settlement Agreement is neither an admission of liability by NeoGenomics nor a concession by the United States that its claims are not well founded, standard language in civil settlements that allows both parties to resolve a matter without either side conceding the underlying merits of the dispute.
What This Means for NeoGenomics Going Forward
With the DOJ settlement now finalized and NeoGenomics’ financial reserve having adequately covered the resolved liability, the company can move forward without this matter continuing to weigh on its regulatory or financial disclosures. The case also serves as a reminder of how voluntary self-disclosure to OIG, even years before a final settlement, can shape the trajectory and terms of healthcare compliance investigations more broadly.
What to Watch Going Forward
As NeoGenomics continues its work in oncology diagnostics and precision medicine, investors and industry observers will likely note that this settlement closes out a matter the company proactively reported rather than one uncovered through external investigation, a distinction that may factor into how the market and future partners view its broader compliance track record.
For more healthcare industry updates, insights and news, visit DistilINFO. Click here to subscribe to stay informed.
